Recombinant IL13: Enhance Your Research with Quality Solutions and Resources

Recombinant IL-13 from Alpha Lifetech Incorporation offers a high-quality solution for researchers investigating the roles of interleukin-13 in immune responses, inflammation, and various diseases. This cytokine, essential in mediating allergic responses and asthma, is produced using cutting-edge recombinant DNA technology to ensure purity, bioactivity, and consistency, With its ability to induce differentiation in B cells and modulate macrophage function, our Recombinant IL-13 is an invaluable tool for exploring therapeutic avenues for conditions such as asthma and autoimmune diseases. Alpha Lifetech’s meticulous production process results in a product that meets the rigorous standards required for advanced research, Our Recombinant IL-13 can be utilized in a variety of applications, including cell culture, functional assays, and drug discovery. Trust Alpha Lifetech Incorporation for reliable, expertly crafted cytokines that propel your research forward with precision and efficacy. Enhance your experiments with our Recombinant IL-13 and open new pathways in your scientific investigations

Hot Selling Product

ADT1162-Dectrekumab Biosimilar-(IL13)-Research Biosimilar Antibody

ADT1126-Cendakimab Biosimilar-(IL13)-Research Biosimilar Antibody

ADT1008-Abrezekimab Biosimilar (IL13)-Research Biosimilar Antibody

ALP64505-Recombinant Human CD24 Protein, mFc Tag

ALP64533-Recombinant Mouse Siglec-15 /CD33L3 Protein, His Tag

ALP64567-Recombinant Rabbit CD86 Protein, His Tag

Trending recombinant il13 Factory Service Backed by Expertise

At Alpha Lifetech Inc., we understand the critical role that recombinant proteins play in advancing biomedical research and therapeutic development. Our expertise, rooted in extensive experience with membrane protein production, Nanobody discovery, and monoclonal antibody development, allows us to provide cutting-edge solutions for researchers and companies around the globe. As we continue to innovate, we are proud to offer our trending recombinant IL-13 factory service, which is tailored to meet the diverse needs of our clients. With nearly 10,000 high-quality spot membrane protein reagents, cytokines, and drug target antibodies in our portfolio, Alpha Lifetech Inc. has emerged as a leader in the biotech sector. Our specialized recombinant IL-13 services not only ensure high purity and activity but also adhere to the stringent regulatory standards required for research and clinical applications. This commitment to quality and reliability positions us as a trusted partner for global buyers seeking to enhance their research capabilities or accelerate drug development processes. Choosing Alpha Lifetech Inc. means opting for excellence backed by scientific knowledge and dedication to customer satisfaction. We invite procurement teams worldwide to explore our offerings and discover how our recombinant IL-13 products can contribute to their groundbreaking research and innovation. Partner with us and benefit from our expertise to drive your next project forward with confidence.

Trending Recombinant IL13 Factory Service Backed by Expertise

Service Type	Expertise Level	Turnaround Time	Client Satisfaction Rate
Recombinant IL13 Production	High	4 Weeks	95%
Custom IL13 Variant Development	Medium	6 Weeks	90%
IL13 Antibody Characterization	Expert	3 Weeks	92%
IL13 Functional Assays	High	5 Weeks	93%
IL13 Based Therapeutics	Advanced	8 Weeks	97%

Monthly Growth of Recombinant IL-13 Production (2022-2023)

The chart above illustrates the monthly growth of recombinant IL-13 production from January 2022 to August 2023. Over this period, we observe a consistent upward trend in production units, indicating increasing demand and advancements in biomanufacturing processes. Beginning at 100 production units in January 2022, production ramped up to 1,100 units by August 2023. This significant growth highlights the expanding role of recombinant proteins in therapeutics, particularly in addressing various conditions linked to interleukin-13, such as asthma and other inflammatory disorders. The data suggests enhancements in technology, regulatory supports, and market needs that collectively drive the recombinant IL-13 sector forward. Continuous monitoring of production metrics can provide insights into future trends and inform stakeholders on capacity planning, ensuring the sustainability of manufacturing efforts to meet patient needs.